Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 531 matching trials from the live ClinicalTrials.gov search.
Conditions
Cancer Diagnosis, Diagnostic Techniques and Procedures, Diagnostic Imaging
Interventions
F-18 FDG, Ga-68-DOTA-TATE, Positron Emission Tomography / Computed Tomography (PET/CT) Scan, Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Hodgkin's Lymphoma
Interventions
Brentuximab Vedotin (SGN-35)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years to 72 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Lung Carcinoma, Esophageal Carcinoma
Interventions
Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Questionnaire Administration
Other · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Neurofibromatosis-1, Optic Glioma, Plexiform Neurofibroma
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
6 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Prostate Neoplasms, Prostatic Cancer, Prostate Cancer, Cancer Of Prostate, Metastatic Prostate Cancer
Interventions
18F-DCFPyL, 18F-FDG, PSMA-11
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Not applicable Interventional Results available

Gated and Non-Gated Dynamic PET/CT Imaging

NCT04283552
Conditions
Dynamic PET/CT Imaging
Interventions
Dynamic PET/CT Imaging
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, aldesleukin, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis
Drug · Biological · Radiation + 2 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Head and Neck Cancer, Carcinoma, Squamous Cell, Head and Neck Cancers
Interventions
PET scan
Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stanford, California
Conditions
Pediatric Cancer
Interventions
Not listed
Lead sponsor
Lars Wagner
Other
Eligibility
12 Years to 29 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Endotoxin-induced iNOS Activation

NCT01407796
Conditions
Pneumonia
Interventions
Endotoxin (E. coli O:113, Reference Endotoxin), [18F](+/-)NOS
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 44 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions
Abemaciclib, Anastrozole, Biospecimen Collection, Computed Tomography, Diagnostic Imaging Testing, Exemestane, Fludeoxyglucose F-18, Fluorine F 18 Fluoro Furanyl Norprogesterone, Fulvestrant, Gonadotropin-releasing Hormone Analog, Letrozole, Positron Emission Tomography, Tamoxifen, Therapeutic Estradiol
Drug · Procedure · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Seattle, Washington
Conditions
Stage IIIA Non-Small Cell Lung Cancer
Interventions
Cisplatin, Computed Tomography, Docetaxel, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Pemetrexed Disodium, Positron Emission Tomography
Drug · Procedure · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Recruiting No phase listed Observational

Smoldering Inflammation in MS

NCT06591429
Conditions
Multiple Sclerosis
Interventions
Radiotracer [11C]-CS1P1, Radiotracer [11C]-DPA-713, anti-CD20 MS treatment, Radiotracer [12F]-FDG
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Lymphoma
Interventions
filgrastim, rituximab, busulfan, cisplatin, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methylprednisolone, prednisone, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, positron emission tomography, fludeoxyglucose F 18, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Breast Cancer, Metastatic Invasive Lobular Breast Cancer
Interventions
18F-FAPI-74, 18F-FDG, PET/CT
Drug · Procedure
Lead sponsor
Randy Yeh
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Terminated Not applicable Interventional Results available

Non-Invasive Characterization in Cardiac Sarcoidosis

NCT02017522
Conditions
Cardiac Sarcoidosis
Interventions
11C-PBR PET
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Fludeoxyglucose F-18, Immunotherapy, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 2 Interventional Results available

18F-FSPG PET/CT for Cancer Patients on Therapy

NCT02599194
Conditions
B-Cell Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Renal Cell Cancer, Progesterone Receptor Negative, Stage III Mesothelioma, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Mesothelioma, Stage IV Non-Small Cell Lung Cancer, Stage IV Renal Cell Cancer, Triple-Negative Breast Carcinoma
Interventions
18F-FSPG, 18F-FDG
Drug
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Stanford, California
Terminated Not applicable Interventional Results available

FDG-PET in Advanced Melanoma

NCT02236546
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
[18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography, computed tomography
Diagnostic Test · Other · Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Joint Prosthesis
Interventions
68-Gallium citrate PET/CT scan, 18F FDG PET/CT scan
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Newark, New Jersey
Conditions
Glioma
Interventions
Fludeoxyglucose F-18, Gadoterate Meglumine, Contrast-enhanced Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Histologically-confirmed Malignancies
Interventions
[18F] FLT, PET/CT scans
Radiation · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Cardiac Disease, Dementia, Inflammatory Disease, Fever of Unknown Origin, Vasculitis, Osteomyelitis, FDG Avid Cancers
Interventions
positron emission tomography, computed tomography, magnetic resonance imaging
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Computed Tomography, Fludeoxyglucose F-18, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
1
States / cities
Seattle, Washington